WO1999064003A1 - Method of treatment of patients with initial liver cancer - Google Patents
Method of treatment of patients with initial liver cancer Download PDFInfo
- Publication number
- WO1999064003A1 WO1999064003A1 PCT/KZ1999/000008 KZ9900008W WO9964003A1 WO 1999064003 A1 WO1999064003 A1 WO 1999064003A1 KZ 9900008 W KZ9900008 W KZ 9900008W WO 9964003 A1 WO9964003 A1 WO 9964003A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- treatment
- patients
- liver cancer
- phtoruracil
- arglabin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
Definitions
- the invention refers to Medicine, concretely to Oncology, to the methods of treatment of patients with initial liver cancer.
- the method of treatment of patients with initial liver cancer by using the combination of Phtoruracil with other preparation of anti tumour effect, for example, doxurubicin, cisplatina, TAMSA, adriablastin, VM-26 and others is known.
- Average human longevity of patients treated with this method varied from 8 weeks to 7 months (Falkson G, Moerte C.G., Lewin P.et al. Chemotherapy studies in initial liver cancer. // Cancer 42 (5), p.2149-2156, 1978; O'Connell M.I., Hahn R.G., Rubin I. Et al.
- Phtoryracil in a day in a dose 500 mg up to common dose 4-6 g.
- Arglabin- is a biologically active sequiterpene lactone, which is produced from perennial plant (wormwood smooth), which grows on the territory of Ukraine.
- the preparation has hepatotropic and anti- tumour effect.
- Application of the proposed method of treatment by Arglabin in combination with Phtoruracil increases of the efficiency of treatment of the patients with initial liver cancer in comparison with known method, as the average human longevity of the patients increases.
- Total number of chemotherapy course in positive treatment effect is 5-6 with the intervals between them 2-3 weeks. Case studies of the implementation of the method.
- liver cancer stage III (T3NOMO).
- T3NOMO diagnosis liver cancer
- the diagnosis was verified cytologically, cytologic conclusion of 25.03.97- hepato-cellular cancer.
- the neoplasm with increased echo-thickness was detected with the sizes 11,0x9,6x9,6 cm. liver sizes 7,4x16,5 x26 cm.
- Partial regress is registered. At present the patient is alive, his state is satisfactory.
- Biochemical blood test of 03.07.96 glucose -3,7 mkmol/1, bilirubin - 14,8-3,6 mkmol/1, thymol sample -7 units, common protein - 74g/l, urea -5,0. alaninaminotransferasa (ALAT)- 348 mmol/1, aspartataminotransferasa (ASAT)-208 mmol/1.
- AOTA alaninaminotransferasa
- ASAT aspartataminotransferasa
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention refers to Medicine, concretely to Oncology, to the methods of treatment of patients with initial liver cancer. The method includes the injection of preparations of anti-tumour effect- Phtoruracil in combination with Arglabin. The method enhances the increase of the efficiency of treatment.
Description
Method of treatment of patients with initial liver cancer
The invention refers to Medicine, concretely to Oncology, to the methods of treatment of patients with initial liver cancer. The method of treatment of patients with initial liver cancer by using the combination of Phtoruracil with other preparation of anti tumour effect, for example, doxurubicin, cisplatina, TAMSA, adriablastin, VM-26 and others is known. Average human longevity of patients treated with this method varied from 8 weeks to 7 months (Falkson G, Moerte C.G., Lewin P.et al. Chemotherapy studies in initial liver cancer. // Cancer 42 (5), p.2149-2156, 1978; O'Connell M.I., Hahn R.G., Rubin I. Et al. Chemotherapy of malignant hepatomas with segnential intraarterial doxorubicin and systematic 5-FU and semustine.// Cancer (Philad.) 62 (6), p.1041- 1043, 1988). Technical result of the invention is the increase of treatment efficiencv.
The result mentioned is achieved in the method of treatment of the patients with initial liver cancer by means of injection of Phtoruracil in a combination with another preparation of anti-tumour effect- Arglabin.
It is preferable to inject Phtoryracil in a day in a dose 500 mg up to common dose 4-6 g.
Arglabin- is a biologically active sequiterpene lactone, which is produced from perennial plant (wormwood smooth), which grows on the territory of Kazakhstan. The preparation has hepatotropic and anti- tumour effect. Application of the proposed method of treatment by Arglabin in combination with Phtoruracil increases of the efficiency of treatment of the patients with initial liver cancer in comparison with known method, as the average human longevity of the patients increases. Total number of chemotherapy course in positive treatment effect is 5-6 with the intervals between them 2-3 weeks. Case studies of the implementation of the method.
Case study 1.
Patient N.. age 58. In March 1997 the patient was hospitalized with diagnosis liver cancer, stage III (T3NOMO). The diagnosis was verified cytologically, cytologic conclusion of 25.03.97- hepato-cellular cancer. In ultra sound examination in the right part, of the liver the neoplasm with increased echo-thickness was detected with the sizes 11,0x9,6x9,6 cm. liver sizes 7,4x16,5 x26 cm. Common blood test of 25.03.97:
19 erythrocytes- 4,3 • 10 71, haemoglobin- 128g/l, rate of erythrocytes sediment (RES) -15 mm/h, leucocytes- 4,5 • 109/1, lymphocytes-26, monocytes-6, trombocytes-2,3 • 10 /l, alphaphetoprotein -25 ME/ml.
The patient underwent chemotherapy on the scheme: Arglabin 300mg intravenous every day within 3 weeks (calculation 5 mg/kg of weight), Phtoruracil 500 mg intravenous in a day- 10 injections. In total 5 courses were undertaken with an interval of 21 day. In ultra sound examination of 25.06.97. in the right part of the liver a neoplasm with increased echo-thickness was detected with the sizes 5,7x3,9x4,6, liver sizes 6,3x12x20 cm. Common blood test of 24.06.97: erythrocytes-4,5 « 1012/l, haemoglobin- 142 g/1, RES- 16 mm/h, leucocytes- 5,1 * 109/l, lymphocytes- 25, monocytes-0, trombocytes- 2,4 • 10π/l, alphaphetoprotein -2,5 ME/ml.
Partial regress is registered. At present the patient is alive, his state is satisfactory.
Case study 2. A patient A., age 68, was hospitalized to Surgery Department on
25.06.96. He had problems beneath right rib and weakness. His state when he was hospitalized to this Department was relatively satisfactory, skin and visible mucous were clear, normal colour, peripheral lymphatic nodes were not extended. In lungs breath was visicular, tones distinct, rhythmic.
Arterial pressure 160/100 mm.pt.st, abdomen soft, painful beneath right rib. Liver hurts when palpated, comes out of the edge of rib (costal) arc at 1 cm. In ultra sound tomography liver is somehow extended in sizes, in the right part there is a tumour like volume neoplasm, of solid heterogeneous structure with rough tuberculous shapes 9x7 cm. Puncture biopsy of liver was made, cytological conclusion of 26.06.96- hepatho- cellular cancer.
Common blood test of 26.06.96: haemoglobin- 125 g/1, RES- 6mm/h, erythrocytes- 4,3 • 1012 /l, leucocytes-3,4 * 109/1, eosinophil-2, bacillary- nucleus -5, segment- nucleus -65, lymphocytes- 27.
Biochemical blood test of 03.07.96: glucose -3,7 mkmol/1, bilirubin - 14,8-3,6 mkmol/1, thymol sample -7 units, common protein - 74g/l, urea -5,0. alaninaminotransferasa (ALAT)- 348 mmol/1, aspartataminotransferasa (ASAT)-208 mmol/1.
The patient underwent chemotherapy on the scheme: Arglabin 300 mg intravenous every day within 15 days, Phtoruracil 500 mg intravenous in a day-8 injections. Treatment is not completed due to developed leucopenia. The patient underwent hemostimulating therapy. He was discharged from the hospital in satisfactory condition, he was recommended to have a repeated course of polychemotherapy within 3 weeks. In control examination in August 1996 his state was satisfactory, skin and mucous clear, lymphatic nodes were not extended. In lungs breath visicular, tones clear. Abdomen is soft, painless, liver is not extended. In ultra sound examination in the right part of the liver a volume tumour neoplasm of heterogeneous structure (7x7) is detected. Common blood test of 1 1.08.96: haemoglobin- 120g/l, RES -
8mm/h, eritrocYtes-4, 1 • 10 /l, leicocytes-3,8 » 10 /l, eosinophil- 1 , bacillary-nucleus -4, segment- nucleus -67, lymphocytes-27.
Biochemical blood test of 1 1.08.96: glucose-3,7 rnkmol/1, bilirubin- 16,3-4,2 mkmol/1, thymol sample- 2 units, common protein-76 g/1, alaninaminotransferasa- 128 mmol/1, aspartataminotransferasa - 38 mmol/1. Patient refused from further polychemotherapy. Patient died on 15.02.98. Human longevity was 19,5 months.
Claims
1. The method of treatment of patients with initial liver cancer, including injection of Phtoruracil in combination with other preparation of anti-tumour effect, which differs in a way that Arglabin is used as a second preparation of anti-tumour effect.
2. Method of claim 1, which differs in a way that Arglabin is injected every day in a dose of 5 mg/kg of weight within 2-3 weeks, but Phtoruracil is injected in a day in dose of 500 mg to common dose of 4-6 g.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KZ980590.1 | 1998-06-09 | ||
| KZ980590 | 1998-06-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1999064003A1 true WO1999064003A1 (en) | 1999-12-16 |
Family
ID=19720792
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/KZ1999/000008 WO1999064003A1 (en) | 1998-06-09 | 1999-06-08 | Method of treatment of patients with initial liver cancer |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO1999064003A1 (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998048789A1 (en) * | 1997-04-26 | 1998-11-05 | Paracure, Inc. Doing Business As Kazak-Paracure | Pharmaceutical compositions of arglabin and arglabin derivatives |
-
1999
- 1999-06-08 WO PCT/KZ1999/000008 patent/WO1999064003A1/en active Application Filing
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998048789A1 (en) * | 1997-04-26 | 1998-11-05 | Paracure, Inc. Doing Business As Kazak-Paracure | Pharmaceutical compositions of arglabin and arglabin derivatives |
Non-Patent Citations (3)
| Title |
|---|
| CHEMICAL ABSTRACTS, vol. 127, no. 1, 7 July 1997, Columbus, Ohio, US; abstract no. 399, SHAIKENOV: "Plant Sesquiterpenes and New Possibilities for Chemotherapy for Oncological Disease" XP002120030 * |
| FALKSON ET AL: "Chemotherapy Studies in Primary Liver Cancer: A Prospective Randomized Clinical Trial", CANCER, vol. 42, no. 5, November 1978 (1978-11-01), pages 2149 - 2156, XP002120029 * |
| SHAIKENOV, ZDRAVOOKHR. KAZ., vol. 1, 1997, pages 52 - 56 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Becton et al. | An experience with an implanted port system in 66 children with cancer | |
| Goldstein | Clinical applications of thymosin alpha-1 | |
| Cihan et al. | Fournier's gangrene after hemorrhoidectomy: Association with drug-induced agranulocytosis: Report of a case | |
| Chandrasekar et al. | Corynebacterium hemolyticum bacteremia with fatal neurologic complication in an intravenous drug addict | |
| WO1999064003A1 (en) | Method of treatment of patients with initial liver cancer | |
| Caughey | Pleuropericardial lesion in Q fever. | |
| De Boer et al. | Low molecular weight heparin treatment in a pregnant woman with allergy to standard heparins and heparinoid | |
| Crum | Effect of cisplatin upon expression of in vivo immune tumor resistance | |
| Jodal et al. | The effect of apamin on non‐adrenergic, non‐cholinergic vasodilator mechanisms in the intestines of the cat. | |
| CN106539815B (en) | Application of the ring dinucleotides in prevention and treatment multiple sclerosis | |
| RU2326657C1 (en) | Method of wound healing | |
| Schubert | Chilaiditi's syndrome: An unsual cause of chest or abdominal pain. | |
| Reboli et al. | Aspergillus myositis in a patient with a myelodysplastic syndrome | |
| Hansson et al. | Fusarium infection with unusual skin lesions in a patient with acute lymphocytic leukemia | |
| Abdi et al. | Combination of Fibroblast Interferon (HuIFNβ), Carboxamide (DTIC), and Cimetidine for Advanced Malignant Melanoma | |
| CN110772507B (en) | Use of guanidine hydrochloride as medicine for treating cancer/tumor | |
| RU2129011C1 (en) | Method of interferon-inducing or interferon-activated therapy and an agent for its realization | |
| RU2005430C1 (en) | Method for treating osteomyelitis of lower extremities | |
| RU2211035C1 (en) | Anti-tuberculosis preparation | |
| 胡金生 et al. | Acupuncture treatment of herpes zoster | |
| CN114533851A (en) | Application of polypeptide Cbf-14 in preparation of analgesic | |
| RU2243780C1 (en) | Method for treating postoperational abscesses of abdominal cavity | |
| Lemonick | Emily's little experiment. | |
| RU2152214C1 (en) | Method for treating the cases of acute osteomyelitis | |
| RU2306149C2 (en) | Method for treating patients at chronic pneumonia due to applying "rusam" |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): CN IN JP TR US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| 122 | Ep: pct application non-entry in european phase |